Guizhong Liu - Adagene Head Pharmacology
| ADAG Stock | USD 2.19 0.07 3.10% |
Insider
Guizhong Liu is Head Pharmacology of Adagene
| Age | 53 |
| Address | Building C14, Suzhou, China, 215123 |
| Phone | 86 512 8777 3632 |
| Web | https://www.adagene.com |
Adagene Management Efficiency
The company has return on total asset (ROA) of (0.1959) % which means that it has lost $0.1959 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.457) %, meaning that it created substantial loss on money invested by shareholders. Adagene's management efficiency ratios could be used to measure how well Adagene manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.17. The current Return On Capital Employed is estimated to decrease to -0.3. At this time, Adagene's Non Current Assets Total are most likely to increase significantly in the upcoming years. The Adagene's current Non Currrent Assets Other is estimated to increase to about 89.1 K, while Return On Tangible Assets are projected to decrease to (0.17).Similar Executives
| Showing other executives | INSIDER Age | ||
| Brian MD | Rezolute | 49 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Joseph Zakrzewski | AN2 Therapeutics | 62 | |
| Michael Alley | AN2 Therapeutics | N/A | |
| MD MBA | Rezolute | N/A | |
| Byron JD | Janux Therapeutics | 59 | |
| Daniel Faga | AnaptysBio | 44 | |
| LLM JD | Rezolute | 63 | |
| Eric Easom | AN2 Therapeutics | 56 | |
| MD FACP | AN2 Therapeutics | 76 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Crystal Mercado | Acrivon Therapeutics, Common | N/A | |
| MBA BS | AN2 Therapeutics | 49 | |
| Hunter MD | Aerovate Therapeutics | 58 | |
| Peter MD | Acrivon Therapeutics, Common | 61 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Leila MD | Pmv Pharmaceuticals | 61 | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| James JD | Eliem Therapeutics | 58 | |
| Rasmus HolmJorgensen | Acrivon Therapeutics, Common | 52 | |
| , MBA | Molecular Partners AG | 51 | |
Management Performance
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.2 |
Adagene Leadership Team
Elected by the shareholders, the Adagene's board of directors comprises two types of representatives: Adagene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adagene. The board's role is to monitor Adagene's management team and ensure that shareholders' interests are well served. Adagene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adagene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Guizhong Liu, Head Pharmacology | ||
| Xiaohong She, Senior Operations | ||
| Ling Zhou, Head Resources | ||
| Man MBA, CFO Director | ||
| Alexander Goergen, VP Development | ||
| Qinghai Zhao, Chief Officer | ||
| Fangyong Du, Chief Officer | ||
| Ami Knoefler, Vice Communications | ||
| Peter Luo, Chairman, Founder | ||
| Yan MBA, Senior Technology | ||
| Jc MD, Chief Officer |
Adagene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adagene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (45.35) % | ||||
| Current Valuation | 25.17 M | ||||
| Shares Outstanding | 44.27 M | ||||
| Shares Owned By Insiders | 10.65 % | ||||
| Shares Owned By Institutions | 25.54 % | ||||
| Number Of Shares Shorted | 12.29 K | ||||
| Price To Book | 1.77 X | ||||
| Price To Sales | 122.65 X |
Currently Active Assets on Macroaxis
When determining whether Adagene is a strong investment it is important to analyze Adagene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adagene's future performance. For an informed investment choice regarding Adagene Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adagene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Adagene Stock please use our How to Invest in Adagene guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adagene. If investors know Adagene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adagene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.72) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.85) | Return On Assets (0.20) | Return On Equity (0.46) |
The market value of Adagene is measured differently than its book value, which is the value of Adagene that is recorded on the company's balance sheet. Investors also form their own opinion of Adagene's value that differs from its market value or its book value, called intrinsic value, which is Adagene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adagene's market value can be influenced by many factors that don't directly affect Adagene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adagene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Adagene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adagene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.